Haleon was spun off from GSK amid investor pressure, showing steady growth but facing debt concerns. See more about HLN stock ...

The US Food and Drug Administration has proposed to remove oral phenylephrine, widely used in cold and cough syrups.

GSK CEO Emma Walmsley said the sector would need to wait to see who is appointed in key roles in the Trump administration to ...

Phenylephrine:CVS pulls cold medicines with the ingredient Companies such as Procter & Gamble and GSK were among several accused ... or remove such drugs from the market. The Consumer Healthcare ...

Editorial Note: Blueprint may earn a commission from affiliate partner links featured here on our site. This commission does not influence our editors' opinions or evaluations. Please view our ...

Haleon backed its full-year guidance despite lower third-quarter revenue and earnings, although organic revenue growth of 6.1% topped its own forecasts.

Kepler Capital analyst David Evans maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) on October 30 and set a price ...

GlaxoSmithKline ranks as one of the largest companies by total sales. The company wields its might across several therapeutic classes, including respiratory, oncology, and antiviral, as well as ...

(Reuters) -Haleon posted an unexpected drop in third-quarter revenue on Thursday, hurt by a weak demand for its painkiller in ...

GSK has received approval for its vaccine, AREXVY, in Canada to prevent LRTD caused by RSV in adults aged 50 to 59 years.

"OMRON Healthcare continues ... with global brands including GlaxoSmithKline, Kraft Foods and Butterball. She brings a proven ...

Total sales of £8 billion for the three months were 2% lower than a year ago, although 2% higher when excluding currency ...